Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest to acquire Clinical Data Inc to add antidepressant Viibryd to portfolio

This article was originally published in Scrip

Executive Summary

Forest Laboratories has entered into a definitive merger agreement to acquire Clinical Data Inc for $30 per share in cash, plus a contingent value (CVR) right worth up to $6 per share based on sales performance milestones of Clinical Data's first-of-its-kind antidepressant Viibryd (vilazodone HCl), which gained FDA approval on 24 January. The CVR is meant to allow the acquiring company to mitigate long-term risk.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts